Beam Therapeutics BEAM 深 滬
等待開盤 04-03 09:30:00 美东时间
24.66
+0.440
+1.82%
華盛通- 最 高24.99
- 今 開23.52
- 成交量 185.40万股
- 最 低 23.52
- 昨 收 24.22
- 總市值 25.12亿
- 52周最高 36.44
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 15.35
- 委 比 -72.72%
- 總股本 1.02亿
- 歷史最高 138.522
- 量 比 0.79
- 振 幅 6.07%
- 歷史最低 13.00
- 每 手 1
- 風險率 4.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Beam Therapeutics Publishes BEACON Phase 1/2 Data For Risto-Cel In Patients With Sickle Cell Disease In The New England Journal of Medicine; U.S. Biologics License Application Submission for Risto-Cel Expected As Early As Year-End 2026
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)Initially Presented at ASH, Data from 31 Patients with SCD
04-02 05:17
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics announced the publication of interim data from the Phase 1/2 BEACON trial in *The New England Journal of Medicine*, demonstrating ristoglogene autogetemcel (risto-cel)'s potential to significantly improve outcomes for patients with sickle cell disease (SCD) and severe vaso-occlusive crises (VOCs). Data from 31 patients showed rapid engraftment, hemoglobin improvements mimicking sickle cell trait, and no severe VOCs post-treatmen...
04-01 21:12
Beam Therapeutics发布BEAM-302临床数据加速AATD治疗赛道分化
声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 29例患者随...
03-29 10:31
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Beam Therapeutics Announces Updated Safety And Efficacy Data From Ongoing Phase 1/2 Trial Of BEAM-302 And Selection Of 60 Mg As Optimal Biological Dose To Advance Into Pivotal Development To Support Potential Accelerated Approval
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-upCorrected M-AAT
03-25 19:09
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Cambridge, MA, March 25, 2026 – Beam Therapeutics announced updated Phase 1/2 trial data for BEAM-302, a base editing therapy for alpha-1 antitrypsin deficiency (AATD). The 60 mg dose achieved mean total AAT levels of 16.1 µM, with all patients consistently above the protective 11 µM threshold. Mutant Z-AAT was reduced by 84%, and adverse events were mild to moderate. Efficacy data support 60 mg as the optimal dose for pivotal development. The co...
03-25 11:00
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
Beam Therapeutics ( ($BEAM) ) just unveiled an update. On March 2, 2026, Beam T...
03-06 05:45
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu
Cathie Wood’s ARK Invest ETFs reallocated majorly to AI and defense names, sharply increasing exposure to high-growth AI software and autonomous technology while cutting enterprise software, semicondu...
03-02 20:18
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
